Lacosamide in status epilepticus: Systematic review of current evidence
| Autor: | Felix Rosenow, Esther Paule, Julie Jost, Sebastian Bauer, Johann Philipp Zöllner, Susanne Schubert-Bast, Adam Strzelczyk, Laurent M. Willems |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Lacosamide Epilepsy Partial Motor Status epilepticus Young Adult 03 medical and health sciences Epilepsy Status Epilepticus 0302 clinical medicine Interaction potential Internal medicine Acetamides medicine Humans 030212 general & internal medicine Child Infusions Intravenous Adverse effect Aged Aged 80 and over Diplopia business.industry Infant Newborn Infant Middle Aged medicine.disease Emergency situations Treatment Outcome Neurology Tolerability Child Preschool Anesthesia Female Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Epilepsia. 58:933-950 |
| ISSN: | 0013-9580 |
| DOI: | 10.1111/epi.13716 |
| Popis: | SummaryObjective The intravenous formulation of lacosamide (LCM) and its good overall tolerability and safety favor the use in status epilepticus (SE). The aim of this systematic review was to identify and evaluate studies reporting on the use of LCM in SE. Methods We performed a systematic literature search of electronic databases using a combined search strategy from 2008 until October 2016. Using a standardized assessment form, information on the study design, methodologic framework, data sources, efficacy, and adverse events attributed to LCM were extracted from each publication and systematically reported. Results In total, 522 SE episodes (51.7% female) in 486 adults and 36 children and adolescents were evaluated with an overall LCM efficacy of 57%. Efficacy was comparable between use in nonconvulsive (57%; 82/145) and generalized-convulsive (61%; 30/49; p = 0.68) SE, whereas overall success rate was better in focal motor SE (92%; 34/39, p = 0.013; p < 0.001). The efficacy with later positioning of LCM decreased from 100% to 20%. The main adverse events during treatment of SE are dizziness, abnormal vision, diplopia, and ataxia. Overall, lacosamide is well tolerated and has no clinically relevant drug–drug interactions. Significance The available data regarding the use of LCM in SE are promising, with a success rate of 57%. The strength of LCM is the lack of interaction potential and the option for intravenous use in emergency situations requiring rapid uptitration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text